Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Inc. (OVID) is a healthcare company (biotechnology) based in the United States. The share price is $2.29, down 4.79% on the day, which values the company at $431.25M. Price as of 17 Nov 2026, 17:26 UTC, from Yahoo Finance.

Key facts

Share price
$2.29−4.79% today
Market value
$431.25M
Funk Score
38/100
Against its own history
Above its usual priceusual price $1.79
200-week average
$2.118% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Ovid Therapeutics Inc. in more detail

OVID trades at -5.6× next year's expected earnings, 296.8× sales. Measured against its own history, the price is 27% above what its usual multiples would imply ($1.79) — above its usual price. It sits 8% above its 200-week average of $2.11.

Over the last five fiscal years Ovid Therapeutics Inc. has compounded revenue -10.5% a year. Its Funk Score is 38 out of 100 (financial strength 8.3, profitability 0.2, growth 5.3, value 1.3, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Share count keeps rising; Heavy stock-based pay.

1 of the superinvestors tracked here hold OVID, including Peter Kolchinsky (0.2% of the portfolio).

Superinvestors holding OVID

1 of the investors tracked here report a position in their latest 13F filing.

Ovid Therapeutics Inc. (OVID): questions and answers

What is Ovid Therapeutics Inc.'s market cap?

Ovid Therapeutics Inc. is valued at $431.25M at a share price of $2.29.

Is OVID overvalued or undervalued?

Against its own history, OVID is above its usual price: the price is 27% above the $1.79 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is OVID above its 200-week moving average?

Yes. OVID is 8.4% above its 200-week average of $2.11. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Ovid Therapeutics Inc. growing?

Over the last five fiscal years Ovid Therapeutics Inc.'s revenue grew -10.5% a year.

Does OVID pay a dividend?

Ovid Therapeutics Inc. does not currently pay a regular dividend.

Which famous investors own OVID?

In their latest quarterly filings, Peter Kolchinsky (0.2% of the portfolio) hold OVID. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Ovid Therapeutics Inc. (OVID) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/OVID

Underlying data: Yahoo Finance; company filings with the SEC.